Search clinical trials for: ER niacin/laropiprant

Total 1135 results

Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)

Diabetes Mellitus Type 2
Merck Sharp & Dohme LLC

Completed

MK0524B Bioequivalence Study (0524B-070)

Dyslipidemia
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

Lipid Efficacy/Tolerability Study (0524A-020)

Primary Hypercholesterolaemia | Mixed Hyperlipidaemia
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)

Dyslipidemia | Primary Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)

Dyslipidemia
Merck Sharp & Dohme LLC

Terminated

A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)

Hypercholesterolemia, Familial | Heterozygous Familial Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

MK0524A Bioequivalence Study (0524A-059)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

Lipid Efficacy Study (0524B-022)(COMPLETED)

Primary Hypercholesterolemia | Mixed Hyperlipidemia
Organon and Co

Completed

To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)

Hypercholesterolemia | Hyperlipidemia
University of Oxford
Merck Sharp & Dohme LLC

Completed

Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE (HPS2-THRIVE)

Cardiovascular Disease | Diabetes Mellitus | Peripheral Arterial Disease | Coronary Heart Disease

United Kingdom
Instituto Aragones de Ciencias de la Salud
Hospital Miguel Servet

Completed

Effect of Niacin in the Lipoprotein (a) Concentration

Hypercholesterolemia

Spain
Rambam Health Care Campus

Unknown

The Effect of Niacin Administration on Oxidative Stress in Patients With Hypercholesterolmia, as Measured by the Use of a Novel Biomarker

Hypercholesterolemia

Israel
Calmy Alexandra
University Hospital, Geneva; Swiss National Science Foundation; Swiss Heart Foundation and other collaborators

Terminated

ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART (NILACH)

Atherosclerosis | HIV

Switzerland
University Medical Centre Ljubljana

Completed

Niacin/Laropiprant and Endothelial Function

Coronary Heart Disease

Slovenia
University of Ioannina

Unknown

Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia

Dyslipidemia

Greece
Merck Sharp & Dohme LLC

Terminated

Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)

Hypercholesterolemia | Mixed Dyslipidemia
Daniel A. Siniawski
Merck Sharp & Dohme LLC

Terminated

Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease

Coronary Artery Disease | Dyslipidemias

Argentina
Merck Sharp & Dohme LLC

Completed

A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)

Rosacea
Merck Sharp & Dohme LLC

Withdrawn

Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)

Dyslipidemia
Merck Sharp & Dohme LLC

Terminated

Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED) (ACHIEVE)

Hypercholesterolemia, Familial
Institut Investigacio Sanitaria Pere Virgili
Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders

Completed

Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment (LOWHDL)

Type 2 Diabetes Mellitus | Dyslipidemia

Spain
Merck Sharp & Dohme LLC

Completed

An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)

Dyslipidemia
Ludwig-Maximilians - University of Munich

Terminated

Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia

Metabolic Syndrome | Hyperlipoproteinemia

Germany
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Effects of Niacin Therapy on Lipoprotein Composition and Function

Cardiovascular Disease

United States
Merck Sharp & Dohme LLC

Completed

Effect of MK0524A on Cholesterol Levels (0524A-048)

Hypercholesterolemia | Hyperlipidemia
Bayside Health
National Health and Medical Research Council, Australia

Terminated

Effects of Niacin on Good Cholesterol in People With Peripheral Arterial Disease

Peripheral Arterial Disease

Australia
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Abbott

Completed

An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME) (SUPREME)

Hyperlipidemia | Mixed Dyslipidemia

United States
Sheba Medical Center

Terminated

The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients

Coronary Artery Disease | Dyslipidemia

Israel
Merck Sharp & Dohme LLC

Completed

MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

MK0524A Phase IIb Study (0524A-011)(COMPLETED)

Flushing
Merck Sharp & Dohme LLC

Completed

Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)

Hyperlipidemia | Hypercholesteremia
University of Pennsylvania

Completed

The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study (GENE)

Healthy Volunteers

United States
Manchester University NHS Foundation Trust

Completed

Effect of Tredaptive on Serum Lipoproteins and Inflammatory Markers

Hypercholesterolemia

United Kingdom
University of Pennsylvania
National Heart, Lung, and Blood Institute (NHLBI); Arizona Pharmaceuticals...

Completed

Effects of Niacin On Fatty Acid Trapping (NOFAT)

Dyslipidemia

United States
Antengene Therapeutics Limited

Recruiting

A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma (TEACH)

Solid Tumor, Non-Hodgkin's Lymphoma

China, Taiwan
Hull University Teaching Hospitals NHS Trust
Merck Sharp & Dohme LLC

Completed

Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome

Polycystic Ovary Syndrome

United Kingdom
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Niacin to Improve Blood Flow in People With Sickle Cell Disease

Sickle Cell Disease

United States
Karyopharm Therapeutics Inc

Terminated

PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) (PANAMA)

Solid Tumors | NHL

United States, Canada
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)

Primary Hypercholesterolemia | Mixed Hyperlipidemia
Lewai Sharki Abdulaziz, MSc PhD
Al-Kindy College of Medicine

Completed

Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females

Atherogenic Dyslipidemia | Obesity Associated Disorder

Iraq
McGill University Health Centre/Research Institute...
CIHR Canadian HIV Trials Network

Completed

Niacin on Immune Activation : a Proof-of-concept Study

HIV

Canada
Merck Sharp & Dohme LLC

Completed

Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Eunice Kennedy Shriver National Institute of Child...

Terminated

Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children

Obesity | Growth Hormone Deficiency | Short Stature

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Withdrawn

To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS

Multiple Sclerosis | Sperm

United States
Iowa State University

Completed

Effects of Nicotinamide Riboside on Metabolism and Vascular Function

Aging | Lipemia

United States

3

Subscribe